Publication:
ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response.

dc.contributor.authorRodríguez-Baena, Francisco Javier
dc.contributor.authorRedondo-García, Silvia
dc.contributor.authorPeris-Torres, Carlos
dc.contributor.authorMartino-Echarri, Estefanía
dc.contributor.authorFernández-Rodríguez, Rubén
dc.contributor.authorPlaza-Calonge, María Del Carmen
dc.contributor.authorAnderson, Per
dc.contributor.authorRodríguez-Manzaneque, Juan Carlos
dc.date.accessioned2023-01-25T10:21:43Z
dc.date.available2023-01-25T10:21:43Z
dc.date.issued2018-08-30
dc.description.abstractRecent advances have emphasized the relevance of studying the extracellular microenvironment given its main contribution to tissue homeostasis and disease. Within this complex scenario, we have studied the extracellular protease ADAMTS1 (a disintegrin and metalloprotease with thrombospondin motif 1), implicated in vascularization and development, with reported anti- and pro-tumorigenic activities. In this work we performed a detailed study of the vasculature and substrates in adult organs of wild type and Adamts1-deficient mice. In addition to the expected alterations of organs like kidney, heart and aorta, we found that the lack of ADAMTS1 differently affects lymphocyte and myeloid populations in the spleen and bone marrow. The study of the substrate versican also revealed its alteration in the absence of the protease. With such premises, we challenged our mice with subcutaneous B16F1 syngeneic tumours and closely evaluated the immune repertoire in the tumours but also in the distant spleen and bone marrow. Our results confirmed a pro-inflammatory landscape in the absence of ADAMTS1, correlating with tumour blockade, supporting its novel role as a modulator of the immune cell response.
dc.identifier.doi10.1038/s41598-018-31288-7
dc.identifier.essn2045-2322
dc.identifier.pmcPMC6117274
dc.identifier.pmid30166561
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117274/pdf
dc.identifier.unpaywallURLhttps://www.nature.com/articles/s41598-018-31288-7.pdf
dc.identifier.urihttp://hdl.handle.net/10668/12886
dc.issue.number1
dc.journal.titleScientific reports
dc.journal.titleabbreviationSci Rep
dc.language.isoen
dc.organizationCentro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica-GENYO
dc.page.number13103
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshADAMTS1 Protein
dc.subject.meshAnimals
dc.subject.meshBone Marrow
dc.subject.meshCell Proliferation
dc.subject.meshInflammation
dc.subject.meshMelanoma, Experimental
dc.subject.meshMice, Inbred C57BL
dc.subject.meshMice, Knockout
dc.subject.meshModels, Biological
dc.subject.meshNeoplasms
dc.subject.meshNeovascularization, Pathologic
dc.subject.meshOrgan Specificity
dc.subject.meshSpleen
dc.subject.meshSubstrate Specificity
dc.subject.meshVersicans
dc.titleADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number8
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC6117274.pdf
Size:
4.21 MB
Format:
Adobe Portable Document Format